Involvement of PKC βII in anti-proliferating action of a new antitumor compound gnidimacrin
Involvement of PKC βII in anti-proliferating action of a new antitumor compound gnidimacrin
复制标题
DOI:
10.1002/ijc.11157
复制
发表时间:
2003-07-10
影响因子:
6.4
通讯作者:
Wakasugi, H
中科院分区:
文献类型:
--
作者:
Yoshida, M;Heike, Y;Wakasugi, H
Daphnane-type diterpene gnidimacrin (NSC 252940) shows significant antitumor activity against murine tumors and human tumor cell lines. This compound binds to and directly activates protein kinase C (PKC), arresting the cell cycle at the G, phase through inhibition of cdk2 activity in human K562 leukemia cells. In our study, we examined whether cellular PKC is involved in the antiproliferating effect of gniclimacrin. In a 24-hr exposure of K562 cells to high concentrations of bryostatin 1 (0.11-3.3 muM), both expression of PKC alpha and PKC betaII was downregulated, and thereafter these cells became resistant to gniclimacrin in response to the degree of PKC downregulation. In addition, PKC alpha and PKC betaII genes were transfected to gnidimacrin-resistant human hepatoma HLE cells that demonstrated positive expression of PKC a and negative expression of PKC betaII. PKC betaII gene-transfected cells became sensitive to gniclimacrin in relation to the degree of PKC betaII expression. The most sensitive clone to show 0.001 mug/mL (1.2 nM) as IC50 in a continuous 4-day exposure was obtained. While PKC alpha gene-transfected cells exhibited an increase in PKC alpha expression and became sensitive to gniclimacrin, sensitivity was one-hundredth of that in PKC betaII gene-transfected cells. These results suggest that PKC, in particular PKC betaII, is necessary in the antitumor effect of gniclimacrin.